Maze Therapeutics (MAZE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Maze Therapeutics (MAZE) is Neutral.

The composite score behind that read is -0.18, weighing +0.27 of bullish evidence against -0.32 bearish.

Maze Therapeutics last closed at $26.25, -0.68% on the session.

Against the IVW growth benchmark the position is -0.52% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

14 graded predictions for MAZE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Maze Therapeutics in the 22nd percentile on return on equity, where 100 is best.

Maze Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.47B.

StockMap tracks Maze Therapeutics as the 54th largest of the 149 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 62 Moderate Underperform, 59 Neutral, 21 Strong Underperform and 7 Moderate Outperform.

On that composite Maze Therapeutics ranks 61st of 149 in the group, against a group median of -0.27.